Platelet-Rich Concentrates in the Management of Lichen Planus—A Comprehensive Review

• Published in: Journal of clinical medicine Vol. 14; no. 15; p. 5368
• Main Authors: Ślebioda, Zuzanna, Rangé, Hélène, Mania-Końsko, Agnieszka, Wyganowska, Marzena Liliana
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.07.2025; MDPI
• Subjects: Authorship; Blood platelets; Case reports; Clinical trials; Cohort analysis; Cytotoxicity; Erythema; Growth factors; Leukocytes; Life Sciences; Medical Subject Headings-MeSH; Patients; Quality of life; Remission (Medicine); Review; Steroids; oral lichen planus; oral pathology; platelet-rich fibrin; platelet-rich plasma; periodontology; Oral lichen planus; Internal medicine; Dermatology; Platelet-rich plasma; Platelet-rich fibrin; Adverse effect; Meta-analysis; Medicine; Fibrin; Platelet; Immunology; Cochrane Library; Etiology
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm14155368

Background: Oral lichen planus is a chronic, potentially malignant disorder affecting the mucous membrane. As the etiology remains not fully understood, the treatment of this condition is mainly symptomatic, involving corticosteroids and other immunosuppressive agents, e.g., calcineurin inhibitors. One of the alternative therapeutic approaches includes platelet concentrates, which are autologous bioactive materials. The aim of this review was to evaluate the effects of platelet concentrates in the treatment of oral lichen planus and to compare them to other therapeutic strategies. Methods: The electronic databases PubMed/Medline, Web of Science, and Cochrane Library were searched for articles published up to 30 March 2025, describing clinical studies focused on oral lichen planus and treatment with platelet concentrates. Results: Fourteen studies describing the effects of oral lichen planus therapy with three types of platelet concentrates (injectable platelet-rich plasma, injectable platelet-rich fibrin, and platelet-rich plasma gel) were included in this review. Comparative strategies included steroids and immunosuppressive agents. The treatment duration ranged from 3 weeks to 2 months. The follow-up period varied from 4 weeks to 6 months. In most of the studies, comparable efficacy was achieved for platelet derivatives and alternative treatments. Two of the studies demonstrated more beneficial effects for platelet concentrates compared to controls, while in one of the studies, more severe adverse reactions were revealed in the platelet group compared to the controls. Conclusions: Autologous platelet concentrates showed comparable efficacy in achieving clinical improvement in patients with oral lichen planus to steroids and immunosuppressive drugs. Platelet derivatives could be considered as an alternative treatment to topical immunosuppressives, especially in steroid-refractory cases.